Monte Rosa Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $123.7M | $75.6M | $0 | — | — |
| Operating income | -$54.2M | -$81.1M | -$143.3M | -$112.4M | -$72.9M |
| Operating expenses | $177.9M | $156.7M | $143.3M | $112.4M | $72.9M |
| Cash from operations | -$22.8M | $42.0M | -$43.8M | -$92.5M | -$59.4M |
| Capital expenditure | $4.7M | $4.0M | $19.0M | $12.9M | $9.7M |
| Free cash flow | -$27.5M | $38.0M | -$62.8M | -$105.4M | -$69.1M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $448.7M | $438.7M | $303.8M | $342.4M | $366.3M |
| Total liabilities | $215.6M | $215.8M | $124.5M | $71.0M | $18.8M |
Shares outstanding 84.5M · Free float 86.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.